SHYH-CHYI LOChang J.-S.Lin S.W.-S.Lin D.-T.2020-03-302020-03-3020020042-9007https://scholars.lib.ntu.edu.tw/handle/123456789/480851Background and Objectives: The red blood cell Mi III phenotype is prevalent in Asia, and its corresponding alloantibody, anti-Mia, has been reported to cause haemolytic transfusion reactions and haemolytic disease of the newborn. However, a complete picture of the immunological characteristics of anti-Mia is still lacking. We therefore conducted a systematic study to evaluate the potential clinical significance of this antibody. Materials and Methods: From April 1999 to March 2000, we identified 60 sera containing anti-Mia among pretransfusion samples at a teaching hospital in Taiwan. These antibodies were tested for immunoglobulin class, thermal range and activity in a monocyte monolayer assay. Results: Thirty-four (57%) of the antibodies were immunoglobulin M (IgM), and 15 retained their activity at 37°C. Of those that were immunoglobulin G (IgG), 96% were of subclasses IgG1 and/or IgG3. Monocyte monolayer assay studies showed that 69% (18/26) of the IgG anti-Mia sera were reactive. Conclusions: Our study justifies the implementation of anti-Mia screening in Taiwan.[SDGs]SDG3alloantibody; erythrocyte antibody; immunoglobulin G; immunoglobulin G1; immunoglobulin G3; immunoglobulin M; Miltenberger antibody; unclassified drug; antibody detection; antibody screening; article; blood group MNSs system; blood transfusion; clinical article; diagnostic value; human; monocyte; newborn hemolytic disease; phenotype; priority journal; screening test; Taiwan; thermal analysis; Erythrocytes; Humans; Immunoglobulins; Isoantibodies; Mass Screening; MNSs Blood-Group System; Phenotype; Taiwanjournal article10.1046/j.1423-0410.2002.00212.x122018462-s2.0-0037714993